Announced details
Successfully freeze-dried the product while maintaining its quality
CellSource has handled more than 130,000 contract processing projects involving cells and other materials (the cumulative period and reference date are not specified in the text)
A joint development relationship under the comprehensive business partnership agreement dated 22 July 2025. The parties jointly developed freeze-drying technology for extracellular vesicles.
Representative Director and President: Ishikawa Kakusei (石川格靖); location: Keihanna Plaza Lab Building, 1-7 Hikaridai, Seika-cho, Soraku-gun, Kyoto Prefecture; founded in Kyoto in 2023. The company manufactures, sells and conducts research and development on liquid formulations, including culture media for regenerative medicine, and provides contract development services.
The specific amount and extent of the impact on financial results have not been disclosed
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Freeze-drying technology for extracellular vesicles, including exosomes, Storage solution for freeze-drying, PFC-FD™, ELSSA OSFree, StemDesign |
| Counterparty | ソラリスバイオ株式会社 |
| Counterparty overview | Representative Director and President: Ishikawa Kakusei (石川格靖); location: Keihanna Plaza Lab Building, 1-7 Hikaridai, Seika-cho, Soraku-gun, Kyoto Prefecture; founded in Kyoto in 2023. The company manufactures, sells and conducts research and development on liquid formulations, including culture media for regenerative medicine, and provides contract development services. |
| Relationship with the Company | A joint development relationship under the comprehensive business partnership agreement dated 22 July 2025. The parties jointly developed freeze-drying technology for extracellular vesicles. |
| Contract Date | 22 July 2025 (comprehensive business partnership agreement) |
| Launch date | CellSource has already begun providing the technology for certain contract projects. ソラリスバイオ is preparing for the future general sale of its storage solution, but the specific launch date has not been disclosed. |
| Applicable area | Regenerative Medicine, Drug delivery systems, Diagnostic markers for malignant tumors and other conditions, Exosome-related fields |
| Quantitative Effects | Successfully freeze-dried the product while maintaining its quality |
| Usage history | CellSource has handled more than 130,000 contract processing projects involving cells and other materials (the cumulative period and reference date are not specified in the text) |
| Impact on Business Performance | The specific amount and extent of the impact on financial results have not been disclosed |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Exosomes have traditionally required strict low-temperature control to maintain their quality, making storage and transport difficult. The purpose of this technology is to facilitate the storage and transport of exosomes while preserving their quality and to expand the range of potential applications for exosomes.